The "Fast Money" traders give their final trades of the day.
Some of the names on the move ahead of the open.
The “Fast Money” traders discuss their final trades for the day including Wynn Resorts, United Airlines, Gilead and Juniper.
The Fast Money traders discuss Gilead surging in the after-hours session.
CNBC's Meg Tirrell reports on the quarterly earnings report for Gilead.
U.S. stock index futures pointed to a slightly higher open on Wednesday, as investors parsed through another batch of major earnings.
Rich Ross, Evercore ISI, discusses Amgen earnings and where else in biotech you can put your money to work. The “Fast Money” traders weigh in.
The busiest week for earnings kicks off on Monday, and investors are eyeing one group in particular: biotech.
Michael Yee, Jefferies managing director, discusses the run in biotech stocks as Vertex soars today.
The “Fast Money” traders discuss their final trades for the day including Avid Budget Group, Decker Outdoor Corp, Gilead Sciences and Twitter.
The “Fast Money” traders discuss which extreme stocks they would trade.
The "Fast Money" traders give you 8 ways to trade some extreme movers this week.
Jim Cramer says tech, bank, and drug stocks are getting a boost from the Trump administration.
CNBC's Dominic Chu reports on signals to watch before buying or selling stock using Bank of America, Gilead and the Powershares QQQ ETF as examples.
“Fast Money” Trader Guy Adami and Chad Morganlander, portfolio manager at Washington Crossing Advisors, talk about whether to buy, sell, or hold Starbucks, Amgen, Costco, Twilio, Gilead and Kroger.
Jim Cramer's not playing games when he relates main street’s hottest toy to the biggest stocks on Wall Street.
Jim Cramer rips through his take on caller favorite stocks, including semiconductor manufacturer Micron.
The high cost of health care in the US is nothing compared to the markup on some prescription medicines. We reveal the most expensive drugs.
Jim Cramer shares his take on caller favorite stocks, including this drugmaker.
One popular biotech-tracking ETF has gained 10 percent this year, and some strategists see more room to run.